A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2019-12-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the regimen limiting toxicities (RLT) and
recommended Phase 2 dose (RP2D) of indoximod in patients with newly diagnosed AML receiving
remission induction chemotherapy with cytarabine and idarubicin.